Sign in
Taking people in United StatesPhase 2

Crossword Puzzles as Brain Training for Mild Cognitive Impairment

Compares crossword puzzle amounts in people with mild cognitive impairment.

Key facts

Who runs it
Columbia University
Where
Durham, Miami, New York, and Seattle, United StatesSee the 4 sites
Trial code
Registry title
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
Status
Recruiting
Phase
Phase 2
People taking part
240 people, planned
Started
17 Dec 2024
Expected to end
31 Aug 2030
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cognitive Training
Record updated
28 July 2026

Who can take part

The trial is looking for people aged 55 to 89 with mild cognitive impairment (memory problems that are not dementia). It compares crossword puzzle training with health education.

Age
55 to 89 years
Sex
All sexes. Women must be past menopause (last period more than 12 months ago).
Disease stage
Mild cognitive impairment, early (EMCI) or late (LMCI). This means memory complaints and a low score on a memory test (WMS-III Logical Memory II), judged by years of education. Montreal Cognitive Assessment (MoCA) score must be ≥ 20/30.
Earlier treatment
People cannot join if they did crosswords or computer brain training once per week or more in the past year. Current use of lecanemab or donanemab is not allowed.
Main reasons for not taking part
  • Dementia of any type, or other brain diseases such as Parkinson's disease, multiple sclerosis or Huntington's disease
  • Schizophrenia, psychosis, bipolar I disorder, unstable depression or active suicidal thoughts
  • Alcohol or drug use disorder now or in the past 6 months
  • Stroke with lasting problems, or medicines that harm thinking
  • Cannot have an MRI scan
Show the full registry criteria (20)Hide the full registry criteria

Who can take part

  • Access to a home desktop or laptop computer or tablet at acceptable internet speed for the study duration
  • Participants need to be 55 to 89 years of age (inclusive) at the time of informed consent
  • Females need to be post-menopausal (last period more than 12 months earlier by history)
  • Subjective cognitive complaints, i.e., memory or other cognitive complaints, e.g., naming/language
  • Meets criteria for cognitive impairment (CI), including either EMCI (early MCI) or LMCI (late MCI), defined as memory impairment documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Story A, Delayed Paragraph Recall) from the Wechsler Memory Scale - III (WMS-III) (the maximum score is 25). The criteria for MCI (includes EMCI and LMCI) and used in COGIT-2 are as follows: EMCI is defined by a WMS-III Logical memory delayed recall score of 3-6 with 0-7 years of education, score of 5-9 with 8-15 years of education, and score of 9-11 with 16 or more years of education. LMCI is defined by a WMS-III Logical Memory delayed recall score ≤ 2 with 0-7 years of education, score ≤ 4 with 8-15 years of education, and score ≤ 8 with ≥ 16 years of education
  • Montreal Cognitive Assessment (MoCA) score ≥ 20/30
  • An informant (relative, friend, other caregiver) who contacts the participant at least weekly is required to provide information about the participant's functioning. This can be a telephone informant in the case of participants who do not have a live-in informant or close significant other. If the informant drops out, an alternate informant can be designated by the participant but the new informant will need to sign the informant information sheet
  • Must be English-speaking: Wide Range Achievement Test (WRAT3) score must indicate at least a 6th grade reading level with a score of ≥ 37

Who cannot take part

  • Use of medications known to have a negative impact on cognition: benzodiazepines in lorazepam equivalents greater than or equal to 1 mg daily, narcotics, anticholinergic medications at ACB Calculator level 3), large number of sedating medications in combination. Current use of lecanemab or donanemab will be exclusionary
  • Contraindication to MRI scan: MRI incompatible pacemakers and metal implants, any other contraindication to MRI. For participants with possible claustrophobia, they must be willing to do the MRI with adjunct lorazepam 0.5 mg to reduce anxiety. For participants who are recruited and are eligible for MRI but are unable to complete the baseline MRI, a repeat MRI for the same time-point can be attempted if the subject is willing. Baseline MRI is required for study inclusion
  • Participation concurrently in another therapeutic clinical trial of a cognitive enhancing drug or device or procedure
  • Diagnosis of dementia of any type
  • Current clinical diagnosis of schizophrenia, schizoaffective disorder, psychosis, or bipolar I disorder (Diagnostic and Statistical Manual of Mental Disorders (DSM-5 TR) criteria)
  • Current or recent (past 6 months) alcohol or substance use disorder (DSM-5 TR criteria)
  • Clinical stroke with residual neurological deficits. While we will not exclude participants with cerebrovascular disease or transient ischemic attacks (TIAs), we do not wish to include participants with a frank clinical stroke because it is not clear that this type of participant is similar to the MCI participant generally, and clear-cut neurological impairment, e.g., hemiplegia/hemiparesis or speech impairment, may compromise the ability to do the procedures and to complete the neuropsychological test battery
  • Presence of any of the following disorders: a) Central Nervous System Infections, with cerebrospinal fluid evidence of meningitis, encephalitis, or other infectious process; b) dementia of any type; c) Huntington's disease; d) Multiple sclerosis; e) Parkinson's disease; f) Other neurologic disorders with focal signs, e.g., amyotrophic lateral sclerosis
  • Acute, severe unstable medical illness in the judgment of the clinician. For cancer, acutely ill participants (including those with metastases) are excluded, but history of successfully treated cancer does not result in exclusion
  • Current unstable or untreated major depression, or active suicidality based on a Suicide Severity Rating Scale (C-SSRS Screen version: positive answer to question 1 or 2 followed by item 6 positive answer leads to exclusion. Negative answer to questions 1 and 2: interview ends and the participant is not excluded for active suicidality)
  • Regular use of crosswords or formal computerized cognitive training platforms averaging once per week or more than once per week in the past year. Eligible participants who join the trial are instructed not to do these procedures on their own during the trial, i.e., independent of the study
  • Geriatric Depression Scale (Short Form) score of ≥ 6

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Mild cognitive impairment or cognitive training

This trial is currently available in United States.

  • Duke University Medical CenterDurham, United StatesContact: Caroline HellegersTaking people
  • University of Miami Miller School of MedicineMiami, United StatesContact: Sebastian EscarfullerTaking people
  • Columbia University Irving Medical CenterNew York, United StatesContact: Lola Nedic, BATaking people
  • University of WashingtonSeattle, United StatesContact: Kristen Gonzalez-FarrisTaking people

About the trial

What the trial wants to find out

Effective, clinically meaningful treatments are lacking for patients with mild cognitive impairment (MCI), which is associated with increased risk of transition to dementia. Cognitive training represents an important therapeutic strategy. In a previous study, crossword puzzles were found to be superior to computerized cognitive training on the primary cognitive outcome and function with decreased brain atrophy. Building on these findings, this study will evaluate and compare the impact of high dose crosswords (4 puzzles per week) to low dose crosswords (1 puzzle per week) and a health education control group on the cognition and function of participants.

The 3 groups in the trial

  • ControlPlacebo, for comparison

    This sample will receive health education. The participant will read chapters from the book, "Living a Healthy Life with chronic conditions," 5th edition, by K Lorig, D Laurent, V Gonzalez, D Sobel, M Minor and M Gecht-Silver, and review chapters with the unblinded study coordinator.

    Treatment: Cognitive Training

  • Low Dose CrosswordExisting treatment, for comparison

    This sample will receive low dose crossword training with one crossword puzzle per week during the first 12 weeks on the Cognifit web-based platform. Subsequent booster sessions will occur at 20, 32, 42, 52, 64 and 78 weeks.

    Treatment: Cognitive Training

  • High Dose CrosswordExisting treatment, for comparison

    This sample will receive high dose crossword training. This sample will receive high dose crossword training with four crossword puzzles per week during the first 12 weeks on the Cognifit web-based platform, followed by booster sessions at 20, 32, 42, 52, 64 and 78 weeks.

    Treatment: Cognitive Training

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
Plain-language title
Crossword Puzzles as Brain Training for Mild Cognitive ImpairmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06601933, who can take part
Publications
Record updated
28 July 2026